ABSTRACT
Objective To investigate the effects of levodopa/carbidopa plus entacapone (LCE) and levodopa/carbidopa (LC) on anxiety, depression, and quality of life (QOL) between patients with Parkinson disease (PD). Methods In total, 120 patients with idiopathic PD were enrolled in this trial and randomized into the experimental (LCE) and control (LC) groups in a 1∶1 ratio to receive treatment for12 weeks. The Hamilton anxiety scale score (HAMA), Hamilton depression scale score (HAMD), 39-item PD QOL questionnaire score (PDQ-39), Unified PD rating scale score (UPDRS), "on" time (h/d), and "off" time (h/d) were measured at each visit (baseline 0, 4, 8, and 12 weeks). Results At the end point (12 weeks), the decrease in the HAMA score from baseline was higher in the LCE group compared with that in the LC group (3.6±1.3, 95％ CI:3.3-3.9 vs 1.3±0.7, 95％ CI:1.1-1.5, P＜0.001), as well as the HAMD score (5.2±1.9, 95％ CI:4.7-5.7 vs 1.2±0.7, 95％ CI:1.0-1.4, P ＜0.001). Similarly, the changes in the PDQ-39 score were evaluated, and the change was compared between the LCE group and the LC group (14.1±7.8, 95％ CI:12.1-16.1 vs 6.9±4.2, 95％ CI:5.8-8.0, P＜0.001). In addition, the LCE group presented better improvement in the UPDRS score (Ⅰ-Ⅳ), "on" time, and "off" time from the baseline than that in the LC group (P ＜ 0.05). Conclusion Entacapone combined with levodopa/carbidopa could significantly improve anxiety, depression, and QOL in patients with PD experiencing wearing-off.
ABSTRACT
ObjectiveTo observe the effect of vinpocetine sustained-release capsules on post-stroke depression and recovery of neurological function. MethodsA total of 64 patients with acute post-stroke depression were randomly divided into Vinpocetine sustained-release capsules group( 34 cases) and control group(30 cases). Conventional therapy was given to both groups. To the treatment group, vinpocetine sustained-release capsules was given at the same time. Depression status was assessed with Hamilton Rating Depression Scale(HAMD). Meanwhile ,Mimi-Mental State Examination( MMSE), National Institutes of Health Stroke Scale(NIHSS) and Activities of Daily Living(ADL)were given in to both groups. ResultsAfter 6 to 12 weeks' therapy, the total score of HAMD, NIHSS and ADL of Vinpoeetine group were significantly lower than the control group ( all P ＜ 0.05 ), MMSE score increased significantly ( P ＜ 0.05 ) in Vinpocetine group. The curative rate and effective rate of Vinpocetine group were 38％ and 91％. It was significantly higher than the 20％ and 73％ of the control group ( all P ＜ 0.05 ). ConclusionVinpocetine sustainedrelease capsules was effective to treat post-stroke depression. It could improve the emotional state of patients and promote the recovery of neurological function.
ABSTRACT
Objective To observe the effect of vinpocetine on monoamine transmitters in cerebral of poststroke depression (PSD)rats and to investigate the mechanism of pharmacotherapeutics on PSD. Methods Rats were divided randomly into the sham-operated group,the normal saline group,the low dose of vinpocetine group and the high dose of vinpocetine group. Giving the left middle cerebral artery occlusion, the PSD rat model was established by unexpected chronic mild stress. When the PSD rat model was established, vinpocetine group was given vinpocetine(5mg/kg, 10mg/kg) and the normal saline group was given normal saline. Then the ethological score of depression was evaluated on 14 and 28 days. The monoamine transmitter in the frontal cortex and hippocampus and brainstem were detected by the fluorospectrophotometry. Results On the 28th day after the model establishment,compared with the normal saline group, the ethological score of depression level was decreased obviously. Compared with the normal saline group, vinpocetine could improve the ethological score of depression level of the PSD rat model, and these concentrations of 5-hydoxytrypatarmine ( 5-HT), noradrenalin ( NE ) and dopamine ( DA ) in the frontal cortex, hippocampus and brainstem. The level of NE ( ( 192.4 ± 34.8 ) ng/g, ( 206. 0 ± 41.7 ) ng/g,(91.1 ±23.0) ng/g] ,5-HT( (494. 1 ± 50.7) ng/g, (599.7 ± 39.2) ng/g, (541.7 ± 62.6) ng/g) and DA ( ( 298.6 ± 32.6) ng/g, ( 297.0 ± 38.1 ) ng/g, ( 85.9 ± 24.3 ) ng/g) in the high dose of vinpocetine group were significantly higher than that in the normal saline group ( NE (92.4 ± 17.5 ) ng/g, ( 131.4 ± 34.8 ) ng/g, (49.0 ±13.6)ng/g;5-HT(367.8 ±87.3) ng/g,(498.7 ± 79.6) ng/g, (320.4 ±59.4) ng/g; DA( 106.1 ±23.0)ng/g,(97.0 ±21.7)ng/g, (50.4 ± 13.8 )ng/g)(P ＜ 0.01 ). There were increased obviously by the high dose than the low dose of vinpocetine group. Conclusion Vinpocetine could treat PSD by increasing the level of monoamine transmitters in PSD rats' brain.
ABSTRACT
The activity of colony stimulating factor ( CSF) in the conditioned medium ( CM ) was studied with combination method of 3H-TdR incorporation assay and agar colony assay. These two assays were demonstrated to be replaceable each other. The mice were administered with nontoxic monophosphoryl lipid A(MPLA) which was derived from a Re mutant of Salmonnella Minnesota Re595. The results showed a significant elevation of CSF in the serum and reaching the top at 12th h and returning to normal by 24th h. There is a significant dose-resoonse relationship. The CSF was induced with accompany of formation of colony inhibiting factor (GIF), some of which were heat sensitive factors. It is suggested that the MPLA may be a potent CSF-inducer.
ABSTRACT
4-Mercuric acetate estrone (4-MF1) is one of steroidal estrogens which have hi-her protective and therapeutic effects on dogs receiving 2.75 Gy of 60Co ?-ray iradiation.Among those experimental groups,the group treated with 4-ME1 15 mg i.m. two days before irradiation had the higest protective effect, all 5 dogs survived;The group treated with 4-ME 1 i.m. twice at 6,48 h after irradiation had the best therapeutic effect. The survival rate was elevated 54.4%(9/15), as compared with the control group.The clinical symptoms were milder, survival time of dead animals longer, and the WBC count higher.